Integrin Beta1 Market, By Type (AXT-108, C-16Y, CLT-28643, SAL-021 and Others), By Indication (Genetic Disorder, Dermatology, Cardiovascular and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Integrin beta-1 is also known as CD29, which is a cell surface receptor that is encoded by ITGB1 gene in humans. The integrins are associates with integrin alpha 1 and integrin alpha 2 to form integrin complexes that function as collagen receptor and forms dimer with integrin alpha 3 to form receptor for netrin 1 and reelin. In cardiac muscle and skeletal muscle, integrin beta-1D isoform is specially expressed and localizes to costameres and abnormal levels of integrin beta-1D cause limb girdle muscular dystrophy and polyneuropathy. Integrin family are membrane receptors involved in cell adhesion and recognition in various processes such as embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. Integrin Beta-1 has three novel isoforms termed as integrin beta-1B, beta-1C, beta-1D. Integrin beta-1B isoforms to be dominant that it inhibits cell adhesion. The Integrin Beta1 Market accounted for US$ XX billion in 2020 and is estimated to be US$ XX billion by 2030 and is anticipated to register a CAGR of XX%.

Increasing prevalence of Genetic disorder and cardiovascular diseases

Increasing prevalence of genetic disorder and cardiovascular diseases are expected to increase the demand for global Integrin Beta-1 market. Changing lifestyles and other activities is expected to boost the market for inhibitor demands during forecast period.

High Unmet Medical needs for patients

Patients are looking forward for advancement in drugs. Further, a large number of companies are now investing into this market to meet the needs of patients. Such companies are contributing for introduction of new drugs with better functionality into market.

However, side effects and fluctuation reimbursement policy by government such challenges might hamper growth of the global market to a certain extent.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Integrin Beta 1 Market is segmented based on the type, indication, and region.

By Type, the Global Integrin Beta 1 Market   is segmented into AXT-108, C-16Y, CLT-28643, SAL-021 and Others. By indication, the market is segmented in Genetic Disorder, Dermatology, Cardiovascular, Others. By region, the Global Integrin Beta 1 Market   is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the integrin Beta 1 market in terms of revenue, due to the developed healthcare system and health awareness among people.

Regional Insights:

On region the global Integrin Beta 1 Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market during forecast period due to developed and well-structured healthcare system. This region majorly focuses in the research field of cancer. Major key players are also in North America. Presence of large number of patients in the U.S. and Canada further contributes market growth. For instance, as per a 2018 report by the World Cancer Research Fund International, the prevalence of cancer in the U.S. is 352.2 per 100,000. As per the same report, Canada also has a high prevalence of cancer with 334 per 100,000.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Integrin Beta 1 Market   is segmented based on the type, indication, and region.

Global Integrin Beta 1 Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Integrin Beta 1 Market includes Avipero Ltd, Clanotech AB, Morphic Therapeutic Inc, Strykagen Corp, Valeant Pharmaceuticals International Inc.

• Strykagen Corp
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Avipero Ltd
•  Clanotech AB
•  Morphic Therapeutic Inc
• Valeant Pharmaceuticals International IncBNTX Inc.

“*” marked represents similar segmentation in other categories in the respective section